Synairgen PLC's (LON:SNG) chief executive Richard Marsden speaks to Proactive London's Andrew Scott soon after announcing positive results from the clinical trial of its drug to tackle the severe symptoms of coronavirus (COVID-19). He says the study could signal a major breakthrough in the treatment of hospitalised patients. The data revealed that people who received SNG001, an inhaled formulation of interferon beta, had a 79% lower risk of developing severe disease compared to those given the placebo.
Synairgen PLC's Richard Marsden hails positive results from study on COVID-19 patients
Quick facts: Synairgen PLC
Price: 167 GBX
Market Cap: £333.86 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE